AbbVie (ABBV) announced submission of a Biologics License Application to the U.S.FDA for trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: